Physician‑Guided · HIPAA Compliant · Discreetly Delivered Nationwide
FDA-Approved Weight Management · GLP-1 Therapy
Wegovy®
The first GLP-1 receptor agonist FDA-approved specifically for chronic weight management. A 68-week clinical program demonstrated up to 15% average body weight reduction in eligible adults.
You will be directed to our licensed telehealth partner to complete your consultation.
Wegovy® (semaglutide 2.4 mg) represents a milestone in the pharmacological management of obesity — the first GLP-1 receptor agonist to receive FDA approval explicitly for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Through The Project Rx and our licensed telehealth partner, adults who meet clinical criteria can access a comprehensive consultation with a licensed provider to determine whether Wegovy® may be appropriate for their long-term weight management goals.
What Is Wegovy®?
Wegovy® is the brand name for semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist developed by Novo Nordisk. While semaglutide was first introduced as Ozempic® for type 2 diabetes management, the higher-dose formulation of Wegovy® received FDA approval in June 2021 specifically for chronic weight management — marking the most significant regulatory advance in obesity pharmacotherapy in nearly a decade.
The distinction between Wegovy® and Ozempic® lies primarily in dose and indication. Both contain the same active molecule — semaglutide — but Wegovy® titrates to a maintenance dose of 2.4 mg weekly, versus Ozempic®'s maximum of 2 mg. This higher dose was specifically studied in the STEP clinical trial program, which was designed around weight management as the primary endpoint rather than glycemic control.
Wegovy® is FDA-approved for use in adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity — such as hypertension, type 2 diabetes, or dyslipidemia. It is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone intervention.
The clinical profile of Wegovy® has generated significant medical and public interest. The STEP 1 trial demonstrated that adults with obesity treated with semaglutide 2.4 mg lost an average of approximately 15% of their body weight over 68 weeks — the largest average weight reduction demonstrated by any approved anti-obesity medication at the time of approval. Approximately one-third of participants achieved 20% or more weight reduction.
Weight management pharmacotherapy is appropriate only when prescribed and monitored by a licensed medical professional as part of a comprehensive care plan. The Project Rx connects patients with licensed providers who can conduct thorough evaluations and guide clinically appropriate treatment.
2021
Year of FDA approval for chronic weight management
~15%
Average body weight reduction in STEP 1 trial (68 weeks)
2.4 mg
Once-weekly maintenance dose after 16-week titration
Mechanism of Action
How Wegovy® Works
Semaglutide in Wegovy® acts on GLP-1 receptors distributed throughout the body — particularly in the brain, gastrointestinal tract, and pancreas — to produce a coordinated set of metabolic effects that support weight reduction. The mechanism underlying Wegovy®'s efficacy is not a single action but a convergence of several complementary effects.
In the central nervous system, semaglutide acts on GLP-1 receptors in the hypothalamus — specifically regions involved in hunger signaling, reward processing, and energy homeostasis. By activating these receptors, semaglutide reduces appetite signals and attenuates the rewarding properties of calorie-dense foods. Many patients report a noticeable reduction in "food noise" — the persistent intrusive thoughts about food that often undermine dietary adherence.
At the level of the gastrointestinal tract, semaglutide slows gastric emptying, extending the time food remains in the stomach after a meal. This delays the return of hunger signals and reduces total caloric intake across the day — without requiring conscious portion restriction. The effect is particularly pronounced with high-calorie meals.
Semaglutide at the 2.4 mg dose also reduces glucagon secretion and promotes glucose-dependent insulin release in the pancreas, which can be beneficial for patients with pre-diabetes or early metabolic dysfunction — even in the absence of diagnosed type 2 diabetes.
Research from STEP 1 suggests that a significant portion of Wegovy®'s weight effect is mediated centrally — through brain-based appetite and reward pathway modulation — rather than solely through peripheral GI effects. This distinguishes semaglutide mechanistically from earlier weight management medications that acted primarily through peripheral pathways.
Hypothalamic Appetite Suppression
Semaglutide activates GLP-1 receptors in the hypothalamus, reducing hunger signals and attenuating the reward-driven desire for calorie-dense foods — addressing the neural drivers of overeating.
Slowed Gastric Emptying
Food moves more slowly through the stomach, extending the sensation of fullness after meals and naturally reducing total daily caloric intake without requiring deliberate restriction.
Metabolic Hormone Regulation
Wegovy® reduces glucagon and promotes insulin release in a glucose-dependent manner, improving the broader metabolic environment and supporting cardiovascular and glycemic health alongside weight reduction.
Candidacy
Who May Be a Candidate
Wegovy® is FDA-approved for a specific patient population: adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related health condition, such as hypertension, type 2 diabetes, elevated cholesterol, obstructive sleep apnea, or cardiovascular disease. This eligibility framework reflects the FDA's assessment that the clinical benefits of Wegovy® outweigh the risks in these patient groups.
During the telehealth consultation facilitated by The Project Rx, your provider will conduct a comprehensive assessment of your eligibility — reviewing your medical history, current medications, metabolic labs, lifestyle factors, and weight history. This evaluation is essential for ensuring that Wegovy® is both clinically appropriate and safe for you individually.
It is important to understand that weight management is a complex medical issue with many contributing factors. Wegovy® is most effective as part of a comprehensive approach that includes behavioral and nutritional support alongside pharmacotherapy. Your licensed provider will discuss expectations, lifestyle optimization, and the importance of ongoing monitoring throughout your treatment.
Insurance coverage for Wegovy® remains variable, though it has improved as more plans have added obesity pharmacotherapy coverage. Your provider and the telehealth platform can assist with the prior authorization process and help explore manufacturer savings programs if applicable.
May Be Appropriate If
- ›BMI ≥30 kg/m² (obesity) without weight-related comorbidity
- ›BMI ≥27 kg/m² (overweight) with hypertension, type 2 diabetes, or dyslipidemia
- ›Adults who have attempted lifestyle interventions with insufficient results
- ›Patients seeking long-term, medically supervised weight management
- ›No personal or family history of medullary thyroid carcinoma or MEN2
- ›No current or recent history of pancreatitis
Not Typically Appropriate If
- —Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- —Type 1 diabetes (not indicated)
- —Current pregnancy or breastfeeding
- —Prior serious hypersensitivity reaction to semaglutide
- —Active pancreatitis or prior pancreatitis
Dosing Overview
Titration Schedule
Wegovy® is initiated at a low dose and titrated over 16 weeks to the target maintenance dose of 2.4 mg per week. This gradual escalation is critical for tolerability — the GI side effects of semaglutide are most pronounced at higher doses, and the titration schedule allows the body to adapt before reaching the full therapeutic dose.
The 16-week titration schedule is longer than that used for Ozempic®, reflecting the higher maintenance dose. Some patients may benefit from a slower titration pace — spending additional weeks at intermediate doses — if they experience significant GI side effects. This can be discussed with and managed by your prescribing provider.
Wegovy® is administered as a subcutaneous injection in the abdomen, thigh, or upper arm, rotating injection sites each week. It is injected on the same day each week. Pens are pre-filled and single-use, with a new pen required each week at the maintenance dose.
Adherence is a critical factor in outcomes. Missing doses or inconsistent use reduces the medication's efficacy and can alter the tolerability profile when resuming. Your telehealth provider will provide guidance on how to manage missed doses and dose interruptions.
Weeks 1–4
Initiation — tolerance phase
0.25 mg/week
Weeks 5–8
Dose escalation
0.5 mg/week
Weeks 9–12
Continued escalation
1.0 mg/week
Weeks 13–16
Near-maintenance dose
1.7 mg/week
Week 17+
Target maintenance dose
2.4 mg/week
* Dose adjustments are determined by your prescribing provider based on response and tolerability. Not all patients advance to higher doses.
Clinical Evidence
What the Research Shows
~15%
Average body weight reduction at 68 weeks vs. 2.4% placebo
STEP 1 trial
69%
Achieved ≥10% body weight reduction on semaglutide
STEP 1 trial
33%
Achieved ≥20% body weight reduction on semaglutide
STEP 1 trial
The clinical evidence for Wegovy® is anchored in the STEP (Semaglutide Treatment Effect in People with obesity) trial program, a series of four Phase 3 randomized controlled trials designed specifically to evaluate semaglutide 2.4 mg for weight management — distinct from the SUSTAIN program, which studied the lower-dose Ozempic® formulation for diabetes.
STEP 1 — the pivotal efficacy trial — enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity (excluding type 2 diabetes). Participants receiving semaglutide 2.4 mg achieved an average weight reduction of approximately 14.9% over 68 weeks, compared to 2.4% with placebo. Nearly 70% of the semaglutide group lost ≥10% of body weight, and approximately one-third achieved ≥20% reduction.
STEP 2 evaluated semaglutide 2.4 mg specifically in adults with type 2 diabetes — demonstrating meaningful weight reduction even in this population that typically responds less robustly to weight management interventions.
STEP 4 assessed the consequences of treatment discontinuation, finding significant weight regain within one year of stopping the medication — reinforcing the understanding that obesity is a chronic condition requiring sustained management rather than a temporary intervention.
These findings establish Wegovy® as the most efficacious anti-obesity medication approved by the FDA at the time of its approval, and the SURMOUNT program for tirzepatide (Zepbound®) has since demonstrated even larger average weight reductions in the dual GIP/GLP-1 class.
Safety Information
Side Effects & Risks
The side effect profile of Wegovy® is qualitatively similar to Ozempic® — both contain semaglutide — but the higher dose used in Wegovy® is associated with a somewhat higher frequency and intensity of gastrointestinal side effects, particularly during dose escalation. The 16-week titration schedule is specifically designed to minimize the impact of these effects by allowing gradual adaptation.
In the STEP 1 trial, approximately 44% of participants on semaglutide 2.4 mg reported nausea compared to 16% on placebo. The majority of GI events were reported as mild to moderate and diminished over time. Discontinuation rates due to side effects were approximately 7% in the semaglutide group — meaning that the large majority of patients were able to continue treatment.
Practical strategies for managing gastrointestinal side effects include: eating smaller, more frequent meals; avoiding high-fat, fried, or spicy foods particularly early in treatment; staying well hydrated; eating slowly and stopping when full; and taking the injection at a consistent time each week. Your licensed provider can also adjust the titration pace if needed.
Common (≥1 in 10)
- · Nausea (most common — often transient with dose adjustments)
- · Diarrhea
- · Vomiting
- · Constipation
- · Abdominal pain
- · Heartburn / acid reflux
- · Fatigue (often early in treatment)
- · Headache
Serious Risks (Discuss with Provider)
- · Pancreatitis (acute — discontinue immediately if suspected)
- · Gallbladder disease (gallstones — higher risk with rapid weight loss)
- · Thyroid C-cell tumors (rodent data; contraindicated in MTC/MEN2 history)
- · Worsening kidney function (particularly with dehydration)
- · Serious hypersensitivity / anaphylaxis (rare)
- · Suicidal ideation (post-market monitoring; report any mood changes promptly)
This safety summary is not exhaustive. Please review the complete FDA prescribing information for semaglutide 2.4 mg with your licensed provider before beginning treatment. Report any unexpected or concerning symptoms to your provider promptly. Serious side effects, while uncommon, require immediate medical attention — do not delay seeking care if you experience severe abdominal pain, signs of allergic reaction, or significant mood changes while taking this medication.
How It Works
The Consultation Process
The Project Rx connects patients with a licensed telehealth partner — LegUp Health — whose network of providers specializes in metabolic health and weight management. The consultation process is fully online, HIPAA-compliant, and designed to be both thorough and efficient.
Patients who are ultimately prescribed Wegovy® fill their prescription through a licensed pharmacy of their choice. Insurance prior authorization support and manufacturer savings program information are available through the telehealth platform. The following outlines the typical process from initial inquiry to ongoing care.
Intake & Health History
Complete a detailed intake form covering your medical history, weight history, previous treatments, current medications, and health goals. This is reviewed by a licensed provider before your consultation.
Telehealth Consultation
A licensed provider meets with you via video or async consultation to evaluate your candidacy, discuss treatment options, and answer your questions about Wegovy® and the management process.
Lab Evaluation
Baseline labs — which may include metabolic panel, HbA1c, lipids, thyroid function, and kidney function — may be ordered to inform the prescribing decision and establish a monitoring baseline.
Prescription & Pharmacy
If clinically appropriate, your provider issues a prescription for Wegovy® to a pharmacy of your choice. Insurance and savings program options are coordinated through the platform.
Monitoring & Support
Ongoing follow-up consultations, dose adjustments, side effect management, and progress monitoring are provided throughout your treatment. Wegovy® requires consistent provider oversight for safe long-term use.
What to Expect
Month-by-Month Overview
Weight loss with Wegovy® is a gradual process, not an overnight result. The STEP 1 trial tracked participants for 68 weeks — over 16 months — to capture the full arc of the medication's effect. The following overview is based on patterns observed in clinical trials and real-world use, but individual experiences vary considerably.
Some patients experience meaningful weight changes early in treatment; others find that their response builds gradually over months. Consistency in dosing, lifestyle adherence, and regular communication with your provider are the most reliable predictors of a positive long-term outcome. Do not judge the medication's effectiveness in the first few weeks — the dose is still titrating and GI adaptation is occurring.
Titration Phase
Gradual dose increases from 0.25 mg to 2.4 mg. The focus is on tolerability. GI side effects are most common during this phase and typically peak around dose transitions. Some early appetite reduction is common.
Full Dose Established
At maintenance 2.4 mg dose, appetite suppression typically intensifies. Many patients report significant reduction in hunger and food cravings. Early to moderate weight reductions become measurable for most patients.
Progressive Weight Reduction
Continued weight loss for most patients. Metabolic markers — blood pressure, fasting glucose, lipid panel — may begin to improve. Physical activity often becomes more comfortable as weight decreases.
Plateau & Long-Term Maintenance
In STEP 1, weight reduction plateaued around 60 weeks before stabilizing. This is normal — a new physiological set point is established. Long-term maintenance requires continued dosing; STEP 4 showed significant regain upon discontinuation.
FAQ
Frequently Asked Questions
Access & Pricing
Starting at $1,349/month
Medication cost is an estimate based on current market pricing without insurance coverage. Coverage varies by plan. Some patients qualify for manufacturer savings programs or insurance coverage when prescribed for obesity management.
Begin Your ConsultationEligibility is determined by a licensed provider following your consultation. Not all patients qualify for a prescription.
Wegovy® is a registered trademark of Novo Nordisk A/S. The Project Rx is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names appearing on this page are used solely for informational identification of the referenced medications. The Project Rx facilitates access to licensed telehealth consultations; we do not manufacture, sell, or dispense prescription medications. All prescription decisions are made exclusively by licensed medical professionals following a clinical evaluation. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Not all patients who complete a consultation will receive a prescription.